Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.

Trial Details

NCT ID
NCT05112991
Phase
PHASE2
Sponsor
3D Medicines (Sichuan) Co., Ltd.
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Envafolimab+Lenvatinib
  • Envafolimab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Volunteer to participate and sign the informed consent form.
  • Has a histologically confirmed diagnosis of endometrial carcinoma (EC). Has Documented evidence of advanced, recurrent or metastatic EC and are not…
  • Failure or intolerance of standard first-line platinum-based chemotherapy regimen for EC.
  • Note: If recurrence occurs during adjuvant/neoadjuvant therapy or within 12 months after completion, adjuvant/neoadjuvant therapy is considered to …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →